The opening price for The Sherwin-Williams Company (NYSE:SHW) was $386.52 and the volume amounted to 0.33 million shares which compares with the average volume of 0.6 million shares. The company stock experienced a -0.81% move to arrive at $385.96.The Sherwin-Williams Company (SHW) Analyst Opinion
The Sherwin-Williams Company has a consensus outperform rating from 23 Wall Street analysts, and the number of shares currently sold short amount to at least 2.12% of shares outstanding. The stock spiked 0.86% last month and is up 43.62 this year. Wall Street is only getting more bullish on the stock, with 16 of analysts who cover SHW having a buy-equivalent rating. Analysts have placed a $418.2 price target on The Sherwin-Williams Company, suggesting a 8.35% gain from recent close. It’s currently trading about -3.08% below its 52-week high.The Sherwin-Williams Company Earnings Surprise
The Sherwin-Williams Company (SHW) surprised the stock market in its last reported earnings when it earned $4.75 a piece versus the consensus-estimated $4.65. Its revenue totaled $4.44 billion up 18.76% from the previous quarter.The Sherwin-Williams Company (NYSE:SHW) Intraday View
This stock (SHW) is ahead of its 52-week low with 48.45%. Its last month’s stock price volatility remained 1.26% which for the week stands at 1.32%. The share price has moved backward from its 20 days moving average, trading at a distance of -1.5% and stays 3.49% away from its 50 days moving average. Over the last five days, shares have faced -2.41% losses and now is up 13.17% since hitting its 200-day moving average of $353.65. The Sherwin-Williams Company (SHW) has made its way to a 12-month gain of 45.25%.
Turning to Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), its shares were trading at $12.85 a retreat of $-0.1, on the trading floor. The stock, after opening at $12.95, touched a high of $13 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.6. Vanda Pharmaceuticals Inc. has 2 buy ratings, 0 holds and 0 sells even after the stock tumbled -32.33% from its high of $18.99 to a $580.82 million market value through last close.Vanda Pharmaceuticals Inc. (VNDA) Consensus Price Target
The company’s consensus rating on Reuter’s scale improved from 1.6 to 2 during a month. Analysts set a 12-month price target of $23 a share. The target implies a 78.99% spike from where the shares are currently trading. Also, the current price highlights a discount of 102.33% to analysts’ high consensus price target.Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Intraday Trading
The counter witnessed a trading volume of 0.34 million shares versus an average volume of 0.64 million shares during last trading session. Its last month’s stock price volatility remained 5.56% which for the week approaches 5.25%. The lowest price the stock reached in the last trading day was $12.75 and compares with the $11.90 52-week low. The stock recovered 7.98% since its low point and has performed -19.44% year-to-date.